Special Issue "Inhalable Formulations for Pulmonary Delivery to Treat Non-small Cell Lung Cancer (NSCLC): Development and In-Vitro Efficacy"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 4979
Interests: biomaterials; lipids; drug delivery; nanomedicines; cancer therapy; PTT; PDT
Special Issues, Collections and Topics in MDPI journals
Interests: TD product development; drug delivery; malignant mesothelioma; lung cancer; pulmonary hypertension
Nowadays, inhalation therapy is receiving much attention among scientists and researchers as the preferred administration route for treating non-small cell lung cancer in addition to other airway diseases. Pulmonary drug delivery via oral inhalation represents a new attractive non-invasive administration route for cancer therapeutics. For successful pulmonary drug delivery, delivery devices such as a nebulizers/inhalers and the formulation of therapeutic agents play an important role. In recent years, significant progress has been made in the development of advanced devices, including a device for powder formulation. Inhalation therapy as well as dry powder formulation and design are currently in the limelight due to their stability, aerodynamic properties, and convenient mode of administration. To ensure successful delivery via oral inhalation, formulation into an appropriate inhalable dosage form with good stability is very important. It is also essential that the formulation is paired with a device that generates an aerosol of the appropriate particle/droplet size to ensure deposition into the desired area of the respiratory tract.
Lung cancers are conventionally treated using oral or intravenous anticancer medications. However, these routes of administration are not ideal, as the required drugs are systemically delivered rather than being targeted to the actual tumor site. Therefore, higher doses may also be needed to achieve sufficiently concentration of drug in the lungs for the treatment purpose, which may consequently cause more adverse effects. The administration route, amount of deposition in the lungs, and therapeutic efficacy of the formulation/drug play a vital role in the treatment process. Inhalation therapy may overcome these limitations, with the actual amount of drug required for the treatment being less because the drugs will be efficiently delivered into the lungs/airways as inhaled aerosols. Lower doses can then be used to attain relatively high local concentrations in the lungs.
This Special Issue will focus on recent advances in treating NSCLC via inhalable formulations.
Dr. Nikesh Gupta
Dr. Nishant S. Kulkarni
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pulmonary drug delivery
- dry powder
- cancer therapy